Progress of MCL-1 and its inhibitors in hematologic malignancies

VernacularTitle:MCL-1及其抑制剂在血液恶性肿瘤中的研究进展
Author: Yuan TENG ¹ ; Lijuan LI ; Liansheng ZHANG
Author Information

1. 兰州大学第二临床医学院，兰州　730000
Keywords: Hematologic neoplasms; Myeloid cell leukemia-1; Inhibitor
From: Journal of International Oncology 2024;51(2):119-122
CountryChina
Language:Chinese
Abstract: Myeloid cell leukemia-1 (MCL-1) is an anti-apoptotic protein that plays a key role in promoting cell survival in multiple myeloma, acute myeloid leukemia and non-Hodgkin lymphoma. MCL-1 is highly expressed in a variety of hematological malignancies, which is one of the important factors leading to poor prognosis and chemoresistance in patients with hematological malignancies. Therefore, MCL-1 is an important therapeutic target for hematological malignancies. Several MCL-1 inhibitors have entered clinical trials, including S63845, AZD5991, S64315, AMG-176, and AMG-397. The treatment plans used for hematological malignancies include monotherapy with MCL-1 inhibitors, as well as combination therapy with B cell lymphoma 2 inhibitors or immunomodulatory drugs, all indicating that MCL-1 inhibitors may be a breakthrough point for targeted treatment of hematological malignancies.